Lymphoma & Plasma Cell Disorders
Feature
Three-drug combo delivers PFS for myeloma in OPTIMISMM trial
Celgene announced the phase 3 trial results, which investigators intend to present at future meetings.
Conference Coverage
TRANSCEND NHL trial identifies window
for CAR T expansion
SAN FRANCISCO – The study shows a correlation between certain patient characteristics and outcomes with the CAR T-cell therapy JCAR017.
News
FDA investigating VTEs related to ECP
The US Food and Drug Administration (FDA) says it is evaluating reports of venous thromboembolism (VTE) in patients treated with the CELLEX...
From the Journals
CLL Index proves accurate in predicting survival, time to treat
A meta-analysis shows that the CLL-IPI is a useful tool with chemoimmunotherapy, but data is lacking about its use with targeted therapies.
Conference Coverage
Mogamulizumab is ‘valuable’ option for CTCL
LA JOLLA, CA—Mogamulizumab is a valuable new therapeutic option for patients with cutaneous T-cell lymphoma (CTCL), according to researchers....
From the Journals
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
News
In situ vaccination eradicates lymphoma, other cancers
Experiments in mice have shown that injecting immune-stimulating agents directly into a tumor can help the immune system eradicate tumors in other...
News
Combo could treat double-hit lymphoma
Existing drugs could be combined to treat double-hit lymphoma (DHL), according to preclinical research published in Science Translational Medicine...
From the Journals
Background color a dermoscopic clue to cutaneous B-cell lymphoma
On dermoscopy, almost 80% of the lesions showed salmon- or yellow- to orange-colored background areas.
From the Journals
Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
Subsequent risk of estrogen receptor–negative breast cancer was elevated irrespective of the type of therapy given for Hodgkin lymphoma.
From the Journals
Frontline brentuximab vedotin improved Hodgkin lymphoma outcomes
The study looked at the addition of brentuximab vedotin to chemotherapy in previously untreated patients with stage III or IV classic Hodgkin...